FAM185A Inhibitors
Chemical inhibitors of FAM185A operate through a series of interactions with the phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathway, which is crucial for the regulation and function of this protein. LY294002 and Wortmannin are both direct inhibitors of PI3K, leading to reduced phosphorylation and subsequent activity of Akt, a kinase upstream of FAM185A. This results in diminished activation of FAM185A due to the lack of necessary signals generated by Akt. Similarly, Triciribine and Perifosine obstruct the Akt signaling; however, Triciribine does so by preventing Akt phosphorylation directly, while Perifosine inhibits its activation by blocking its translocation to the cell membrane. Both lead to reduced functional activity of FAM185A by directly targeting the activity of Akt.
Furthermore, GSK690693 and MK-2206, as Akt inhibitors, disrupt the downstream signaling essential for the activation of FAM185A. GSK690693 competes with ATP to reduce Akt activity, while MK-2206 induces a conformational change in Akt, which leads to its inactivation. In addition, inhibitors like Miltefosine and AZD5363 act on the same pathway by different mechanisms. Miltefosine disrupts various signaling pathways including the PI3K/Akt pathway, reducing the downstream signaling necessary for the function of FAM185A. AZD5363, on the other hand, specifically targets Akt to inhibit its function, which in turn affects the activity of FAM185A. Lastly, compounds such as Palomid 529, PF-04691502, and ZSTK474 take a broader approach by targeting both PI3K and mTOR or by acting as a pan-class I PI3K inhibitor, respectively. These compounds diminish the signaling through the PI3K/Akt/mTOR pathway, leading to a comprehensive inhibition of the function of proteins like FAM185A that are regulated by this pathway. Each inhibitor, by its unique interaction with the pathway, ensures a decrease in the functional activity of FAM185A, though they achieve this through different points of intervention in the signaling cascade.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in the Akt signaling pathway. Inhibition of PI3K leads to a decrease in Akt phosphorylation and activity. As family with sequence similarity 185 member A is a part of the PI3K/Akt pathway, the reduction in Akt activity would result in the inhibition of downstream targets including FAM185A. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent and irreversible inhibitor of PI3K. By inhibiting PI3K, wortmannin disrupts the PI3K/Akt pathway, reducing the phosphorylation and subsequent activity of Akt. This decrease in Akt activity inhibits the function of proteins that are regulated by the Akt pathway, including FAM185A. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mechanistic target of rapamycin), which is an important part of the PI3K/Akt/mTOR pathway. Through the inhibition of mTOR, rapamycin reduces the signaling that contributes to the regulation and function of proteins like FAM185A that are downstream in this pathway. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is a specific Akt inhibitor that prevents the phosphorylation and activation of Akt without affecting PI3K, therefore directly targeting the pathway that influences the activity of FAM185A. As a result, the inhibition of Akt results in reduced activity of FAM185A. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an alkylphospholipid that inhibits Akt activation by preventing its recruitment to the plasma membrane, which is necessary for its activation by PI3K. This inhibition of Akt affects the downstream signaling cascade, leading to the inhibition of FAM185A function. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an ATP-competitive inhibitor of Akt. By inhibiting Akt, this compound disrupts the downstream signaling that would normally result in the activation of proteins such as FAM185A, leading to their functional inhibition. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $182.00 $332.00 | 67 | |
MK-2206 is an allosteric inhibitor of Akt that induces a conformational change, reducing its activity. This decrease in Akt activity leads to the inhibition of downstream proteins like FAM185A that are influenced by Akt signaling. | ||||||
Miltefosine | 58066-85-6 | sc-203135 | 50 mg | $81.00 | 8 | |
Miltefosine is an alkylphosphocholine compound that disrupts various signal transduction pathways, including the PI3K/Akt pathway. This disruption leads to the inhibition of the Akt-dependent function of proteins such as FAM185A. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363 is an inhibitor of Akt. By targeting Akt, AZD5363 inhibits the phosphorylation and activation of downstream proteins in the Akt pathway, including FAM185A, resulting in their functional inhibition. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 is a dual TOR/PI3K inhibitor that impairs the PI3K/Akt/mTOR pathway. By inhibiting components of this pathway, the functional activity of downstream effectors like FAM185A is inhibited. | ||||||